Boosting the Secretion of GLP-2 and GLP-1 Intestinal Hormones by Nutrients
NCT ID: NCT01727583
Last Updated: 2013-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
18 participants
INTERVENTIONAL
2012-09-30
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Glucagon-like Peptide 2 on Gallbladder Motility After a Meal in Young, Healthy Male Subjects
NCT03682172
Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like Peptide 2
NCT01958775
Effects of GLP-1 Formula on GLP-1 and Glucose Regulation
NCT07082062
Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome
NCT00673751
Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans
NCT06333496
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lipid 1
Meal intake
meal intake
Intake of meals characterized by lipid composition
Lipid-free
Maltodextrine + proteins
Placebo
Lipid 2
Meal intake
meal intake
Intake of meals characterized by lipid composition
Lipid 3
Meal intake
meal intake
Intake of meals characterized by lipid composition
Lipid 4
meal intake
meal intake
Intake of meals characterized by lipid composition
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
meal intake
Intake of meals characterized by lipid composition
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal fasting glycemia
* Having obtained his informed consent.
Exclusion Criteria
* Have had a gastrointestinal surgery (with the exception of appendices resection).
* Malabsorption disorders
* Lactose intolerance
* Significant weight loss during the past three months (more than 5% of initial weight)
* Have a regular consumption of medication
* Regular supplements (vitamins and minerals) intake during the previous month
* Have an alcohol intake: \> 2 units a day
* Smoker (more than 2 cigarettes a day)
* Illicit substances intake, as stated on the medical screening questionnaire
* Allergy to any food or medication
* Anaemia defined by a number of erythrocytes or hemoglobin Hb or hematocrit Ht which are inferior to laboratory normal ranges
* Having given blood in the past three months or willing to give blood in the 3 months following the completion of the study
* Intense physical activity \> 3 hours per week
* Currently participating or having participated in another clinical trial during the past month.
* Volunteer who cannot be expected to comply with the protocol, including consuming rapidly the study products, chronic medication intake
20 Years
40 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Société des Produits Nestlé (SPN)
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maurice Beaumont, MD
Role: PRINCIPAL_INVESTIGATOR
Nestlé / CDU / Metabolic Unit
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nestlé CDU / Metabolic Unit
Lausanne, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12.10.MET
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.